Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Peking University Cancer Hospital & Institute
Children's National Research Institute
M.D. Anderson Cancer Center
Georgetown University
Peking University Cancer Hospital & Institute
Emory University
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Sichuan University
Hebei Medical University Fourth Hospital
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Shenzhen Geno-Immune Medical Institute
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Stanford University
University of California, San Francisco
The First Affiliated Hospital of Xiamen University
University Health Network, Toronto
Medical College of Wisconsin
National Cancer Centre, Singapore
Chinese PLA General Hospital
National Cancer Centre, Singapore
Universitair Ziekenhuis Brussel
Tianjin Medical University Second Hospital
Peking University Cancer Hospital & Institute
The First Affiliated Hospital of Zhengzhou University
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Peking University Cancer Hospital & Institute
Fudan University
China Medical University, China
Shenzhen Geno-Immune Medical Institute
The First Affiliated Hospital with Nanjing Medical University
Miller Children's & Women's Hospital Long Beach